ABSTRACT
AIM OF THE STUDY: Influence of two hormonal therapies (GnRH agonist--leuprolein acetate and a new progestin--dienogest) on symptoms of endometriosis in patients with different clinical grade of disease. MATERIAL AND METHODS: 34 women with endometriosis confirmed by laparoscopy and histology were included into the study. Patients were randomized and divided into two therapeutic groups. One group was treated with dienogest and the second with leuprolein acetate during 6 month of study. The intensification of pain was assessed with Visual Analog Scale (VAS) and pelvic symptoms scale before, during (3 month) and after therapy. Dyspareunia was assessed with pelvic symptoms scale before, during (3 month) and after therapy. Frequency of adverse effects was assessed in 1, 3 and 6 month of therapy. Emotional state, bone density and basic serum parameters were assessed before and after therapy. RESULTS AND CONCLUSIONS: Dienogest as well as leuprolein acetate decreased pelvic pain and dyspareunia. There were no differences between these influences. Dienogest did not reveal androgenic activity (did not reveal activity nor intense seborrheic lesions, nor hirsutism, nor voice tone). Dienogest did not reveal hot flashes. Bleeding (caused by dienogest therapy) did not influence hematologic indices nor affected the patients' decision on preterm end of treatment.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Endometriosis/drug therapy , Nandrolone/analogs & derivatives , Nandrolone/therapeutic use , Pelvic Inflammatory Disease/drug therapy , Adult , Female , Humans , Severity of Illness Index , Treatment OutcomeABSTRACT
A casuistic case has been presented with endometriosis of the lung in an 18-year-old girl. Several diagnostic difficulties including haemoptysis accompanying changes in the hings and chest, suggesting a npl process. The final diagnosis has been made after the second thoracotomy and was confirmed by the histopathological examination of the lungs and pleurae. Because of the patient's age the a-GnRH therapy was not taken and the treatment with new progestin (dienogest) was administered. The 4-months therapy have appeared to be fully positive without any side effects.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Endometriosis/diagnosis , Endometriosis/drug therapy , Lung Diseases/diagnosis , Lung Diseases/drug therapy , Nandrolone/analogs & derivatives , Nandrolone/therapeutic use , Thoracotomy/methods , Adolescent , Female , HumansABSTRACT
The causes of Pregnancy Induced Hypertension are still under study. A genetic cause has been suggested as well as raised activity of the blood lipid system, which is however determined genetically. One element of the lipid system is lipoprotein a, which may have a key role in prediction of preeclampsia. The aim of our study was to determine lipoprotein (a) concentration in women with preeclampsia and in healthy pregnancies, and to assess the usefulness of lipoprotein (a) concentration as prognostic factor of eclampsia. Sera from 19 women with preeclampsia and from 19 with healthy pregnancies were tested. Our results show that determination of lipoprotein (a) levels in preeclampsia may be significant as predictive factor of eclampsia.
